Today: 16 June 2026
Browse Category

NASDAQ:CRNX 26 September 2025 - 7 January 2026

Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals shares fell about 8% Thursday after a regulatory filing disclosed Chief Medical and Development Officer Dr. Dana Pizzuti will step down December 31. She will transition to a Strategic Regulatory and Development Advisor role in early 2026. The stock traded in the low-to-high $40s as investors reacted to the leadership change.
18 December 2025
·
Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Electronic Arts shares jumped 15% after agreeing to a $55 billion buyout led by Saudi Arabia’s PIF, offering $210 per share. Crinetics Pharmaceuticals soared 28% as the FDA approved its oral acromegaly drug. QMMM Holdings surged 19% before the SEC halted trading over suspected manipulation. Scholar Rock gained 12% despite an FDA delay for its spinal atrophy drug.
29 September 2025
·····
Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Crinetics Pharmaceuticals shares surged 28% to around $46 on Sept. 26 after the FDA approved its first drug, Palsonify, for acromegaly. Trading volume spiked nearly tenfold amid heavy short-covering. The company plans to launch Palsonify in October at a $290,000 annual list price. Crinetics holds $1.2 billion in cash and no debt, with analysts raising price targets following the approval.
26 September 2025
··

Stock Market Today

  • Jardine Matheson Commits to 5% Annual Dividend Growth, $500 Million Buyback
    June 15, 2026, 10:38 PM EDT. Jardine Matheson Holdings (JMH) announced a commitment to grow dividends by at least 5% annually through 2030 and launched a $500 million share buyback program. The conglomerate targets a 9% annual total shareholder return over five years and plans to recycle $4 billion in capital excluding subsidiaries. JMH will pursue control stakes in market-leading Asia-Pacific businesses adopting technology like AI. CEO Lincoln Pan emphasized JMH's shift from an owner-operator to a return-focused investment firm. Shares rose 4.3% to $66 on Monday following the announcement.

Latest articles

Nasdaq steady in late trading as oil eases, Fed up next

Nasdaq steady in late trading as oil eases, Fed up next

16 June 2026
U.S. stocks soared Monday as falling oil prices and a preliminary U.S.-Iran deal fueled a relief rally, with the Nasdaq up 3.07%, S&P 500 up 1.65%, and Dow closing at a record high; after-hours futures dipped slightly as investors awaited Wednesday’s pivotal Federal Reserve decision and Chair Kevin Warsh’s first post-meeting press conference.
Intel stock gains after BofA upgrade, foundry business in focus

Intel Gains as Chip Shares Recover

16 June 2026
Intel surged to $127.86, topping analyst targets, as chip stocks rallied on easing inflation and AI optimism, but the stock’s gains outpace consensus expectations and recent earnings remain negative; investors now await the unconfirmed July 23 earnings report for proof that demand is driving real revenue growth.
Dave & Buster’s falls after Q1 comes up short, comps slip

Dave & Buster’s falls after Q1 comes up short, comps slip

16 June 2026
Dave & Buster’s shares plunged 4.72% to $12.32, then dropped another 11.2% after hours, after Q1 revenue, adjusted profit, and comparable-store sales all missed expectations; management’s guidance for positive sales trends and free-cash-flow remains the next key catalyst as investors weigh the company’s turnaround credibility.
Go toTop